Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852605 | 0.84 | DHODH (0.49) | DHODHKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL7523844 | 0.80 | DHODH (0.58) | DHODHADORA2AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4849634 | 0.73 | MAPT (0.45) | DHODHADORA2AKMT2AMEN1NTSR1 | |
| SCHEMBL1256551 | 0.73 | ACHE (0.61) | DHODHSMN1; SMN2LMNACYP2C9HPGD | |
| SCHEMBL20696076 | 0.72 | ACHE (0.59) | DHODHSMN1; SMN2LMNACYP2C9HPGD | |
| Methane SCHEMBL10433561 | 0.72 | ACHE (0.59) | DHODHSMN1; SMN2LMNACYP2C9HPGD | |
| SCHEMBL9381085 | 0.71 | DHODH (0.46) | DHODHKMT2AALDH1A1KDM4EGAA | |
| SCHEMBL16776799 | 0.70 | ADORA2A (0.47) | DHODHADORA2AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL12201040 | 0.68 | ESR1 (0.53) | DHODHKMT2AMEN1NTSR1SMN1; SMN2 | |
| SCHEMBL10610649 | 0.67 | KDM4E (0.66) | KMT2AMEN1MAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-6423711-B1 | USEFUL IN DIAGNOSIS AND THERAPY OF ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, AND OVERDOSE WITH BENZODIAZEPINE DRUGS AND FOR ENHANCEMENT OF ALERTNESS | NEUROGEN CORPORATION | 2002-07-23 | — | — | US | disclosed |
| US-20020077474-A1 | Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands | NEUROGEN | 2002-06-20 | — | — | US | disclosed |
| US-6380209-B1 | HIGHLY SELECTIVE AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GABA BRAIN RECEPTORS OR PRODRUGS, USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS | NEUROGEN CORPORATION | 2002-04-30 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
| US-6166203-A | Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6103903-A | ANXIOLYTIC AGENTS, ANTICONVULSANTS, COGNITION ACTIVATORS | NEUROGEN CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| WO-1999043681-A1 | 4-(4-PIPERIDYLMETHYLAMINO) SUBSTITUTED HETEROARYL FUSED PYRIDINES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077474-A1 | Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands | GABRA1, GABRA2, GABRA3 | DHODH 3178/4885ADORA2A 67/4885KMT2A 1569/4885 |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | DHODH 2286/4885ADORA2A 81/4885KMT2A 808/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | DHODH 2509/4885ADORA2A 73/4885KMT2A 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.